New Phase 3 AFFIRM data show higher rates of clinical and endoscopic response in Crohn's disease patients treated with subcutaneous SKYRIZI versus placebo across all efficacy endpoints ...
Met-directed antibody-drug conjugate (ADC) with a novel topoisomerase 1 inhibitor (Top1i) being studied in advanced solid tumors ...
AbbVie presents 60 abstracts and presentations from a robust portfolio spanning across alopecia areata, atopic dermatitis, hidradenitis suppurativa, non-segmental vitiligo, psoriasis and ...
RINVOQ is the first and only systemic medication approved in the European Union to treat adult and adolescent patients with non-segmental vitiligo (NSV) who are candidates for systemic ...
AbbVie (NYSE: ABBV) will announce its third-quarter 2026 financial results on Friday, October 30, 2026, before the market opens. AbbVie will host a live webcast of the earnings conference call ...
Phase 2 data in adults with atopic dermatitis showed that all three zumilokibart dose regimens met the primary endpoint, with significantly greater improvements in Eczema Area and Severity ...
AbbVie has been approved to participate in the Health Resources and Services Administration (HRSA) Office of Pharmacy Affairs (OPA) 340B Rebate Model Pilot Program. Beginning January 1, 2027, covered ...
For further information: Media: Gabby Tarbert, (224) 244-0111; Investors: Liz Shea, (847) 935-2211; Todd Bosse, (847) 936-1182; Jeffrey Byrne, (847) 938-2923 The information in the press releases on ...
The information in the press releases on these pages was factually accurate on the date of publication. These press releases remain on AbbVie's website for historical purposes only. AbbVie assumes no ...
The information in the press releases on these pages was factually accurate on the date of publication. These press releases remain on AbbVie's website for historical purposes only. AbbVie assumes no ...
This Phase 3 study enrolled a predominantly treatment-refractory population** (65%) with 50% of those patients having failed two or more advanced therapies and 23% having failed ustekinumab and 12% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results